By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Elusys Therapeutics, Inc. 

25 Riverside Drive
P.O. Box 102
Pine Brook  New Jersey  07058  U.S.A.
Phone: 973-808-0222 Fax: 973-808-0322


SEARCH JOBS


Industry
Biotechnology






Company News
Elusys Therapeutics, Inc. Announces That Manuscripts For Its Anthrax Antitoxin, ANTHIM (Obiltoxaximab) Injection, Have Been Accepted For Publication 7/20/2016 10:14:17 AM
Elusys Therapeutics, Inc. Receives FDA Approval For ANTHIM (obiltoxaximab) Injection For The Treatment And Prophylaxis Of Inhalational Anthrax 3/21/2016 8:22:46 AM
Elusys Therapeutics, Inc. Receives First Delivery Order From U.S. Government For Anthim (obiltoxaximab) For Treatment Of Inhalational Anthrax 11/12/2015 2:04:25 PM
Elusys Therapeutics, Inc. Awarded Additional $16 Million Under Existing U.S. Government Contract To Complete Development Of Lyophilized Form Of Anthim (Obiltoxaximab) For Treatment Of Inhalational Anthrax 10/6/2015 8:37:41 AM
Elusys Therapeutics, Inc. Release: U.S. FDA Accepts Biologics License Application For Anthim (Obiltoxaximab) 6/1/2015 10:40:47 AM
Elusys Therapeutics, Inc. Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 9/22/2014 10:39:54 AM
Elusys Therapeutics, Inc. Completes Commercial Manufacturing Process Validation For Anthrax Antitoxin ETI-204 4/9/2014 8:38:10 AM
Elusys Therapeutics, Inc. Completes Enrollment In Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, ETI-204, In Adult Volunteers 2/5/2014 8:20:07 AM
Elusys Therapeutics, Inc. Releases New Data on Anthrax Anti-Toxin Administered Via Intramuscular Injection From Three Recent Animal Studies 8/1/2013 8:58:55 AM
Alliance for Biosecurity Elects Chief Executive Officers of Bavarian Nordic (BAVA.CO) and Elusys Therapeutics, Inc. as New Co-Chairs 7/1/2013 8:17:59 AM
12345
//-->